Notice of Results

RNS Number : 8943H

Hikma Pharmaceuticals Plc

01 March 2010

 



Hikma will release its 2009 preliminary results on Wednesday, March 17, 2010

LONDON, 1 March 2010 - Hikma Pharmaceuticals PLC ("Hikma") (LSE: HIK) (Nasdaq Dubai: HIK), the fast growing multinational pharmaceutical Group, will release its 2009 preliminary results on Wednesday, 17 March 2010. The company will host a presentation for analysts at 9am and a live webcast of the presentation will be available on Hikma's website. www.hikma.com 

-- ENDS --

Enquiries:

Hikma Pharmaceuticals PLC

Said Darwazah, Chief Executive Officer

Bassam Kanaan, Chief Financial Officer  

Susan Ringdal, Investor Relations Director                       Tel: [phone]

Brunswick Group

Jon Coles / Justine McIlroy                                             Tel: [phone]

Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products.  Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based principally in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe.  In 2008, Hikma achieved revenues of $581 million and profit attributable to shareholders of $57 million.  For news and other information, please visit www.hikma.com.

 

END

 

 

NORDMGGFNMVGGZM